U.S. Markets open in 6 hrs 42 mins
S&P Futures
4,208.25-38.25(-0.90%)Dow Futures
33,952.00-336.00(-0.98%)Nasdaq Futures
13,867.75-162.50(-1.16%)
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.33-0.25 (-2.36%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 10.58 |
| Open | 10.53 |
| Bid | 10.08 x 1100 |
| Ask | 10.09 x 800 |
| Day's Range | 10.02 - 10.58 |
| 52 Week Range | 7.48 - 14.14 |
| Volume | 279,274 |
| Avg. Volume | 283,536 |
| Market Cap | 416.938M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.52 |
| Earnings Date | Aug 04, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.63 |
- Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology reports inducement awards granted in May 2021 as required under Nasdaq Listing Rule 5635(c)(4) .
- Business Wire
Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting
Puma Biotechnology presented data from the EGFR Exon 18-mutant NSCLC cohort of the Phase II SUMMIT Trial on June 4 at the 2021 ASCO Annual Meeting.
- Business Wire
Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting
Puma Biotechnology presented data from the Phase II CONTROL Trial regarding neratinib dose escalation at the ASCO 2021 Annual Meeting.
© 2021 Verizon Media. All rights reserved.
